Know Cancer

or
forgot password

Phase 1 Study Of SNX-5422 Mesylate In Adults With Refractory Solid Tumor Malignancies And Lymphomas


Phase 1
18 Years
N/A
Not Enrolling
Both
Solid Tumor Malignancy, Lymphoid Malignancy (Lymphoma and CLL), Leukemia, Lymphoma

Thank you

Trial Information

Phase 1 Study Of SNX-5422 Mesylate In Adults With Refractory Solid Tumor Malignancies And Lymphomas


Inclusion Criteria:



- Solid tumors or lymphoid malignancies refractory to standard therapy

- measurable disease

- recovery to Grade < 1 toxicity due to prior adverse event or chemotherapy

- no chemotherapy within 4 weeks of entering study

- Age > 18 years

- Karnofsy >= 60%

- Life expectancy > 3 months

- normal or adequate organ and marrow function

Exclusion Criteria:

- receiving other investigational agents

- brain metastases

- uncontrolled medical illness

- HIV+ receiving combination antiretroviral therapy

- significant GI disease

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

MTD, safety and toxicity

Outcome Time Frame:

continuous

Safety Issue:

Yes

Principal Investigator

Pfizer CT.gov Call Center

Investigator Role:

Study Director

Investigator Affiliation:

Pfizer

Authority:

United States: Food and Drug Administration

Study ID:

B1311003

NCT ID:

NCT00647764

Start Date:

March 2008

Completion Date:

September 2010

Related Keywords:

  • Solid Tumor Malignancy
  • Lymphoid Malignancy (Lymphoma and CLL)
  • Leukemia
  • Lymphoma
  • Neoplasms
  • Leukemia
  • Lymphoma

Name

Location

Pfizer Investigational SiteWestminster, Maryland  21157